Abstract
Our objectives were to evaluate the behavior of different doses of pre-operative methotrexate (MTX) pharmacokinetics, and assess correlations between the osteosarcoma histologic response and MTX serum peak concentrations. In total, 336 patients with osteosarcoma of the extremities were treated with three neoadjuvant protocols of chemotherapy including high-dose MTX (different doses for each protocol), cisplatin and doxorubicin (same doses in all protocols). The doses of MTX were 8 g/m in 124 patients, 10 g/m in 110 patients and 12 g/m in 102 patients. The mean value of peak serum MTX was 801 μmol/l (range 298-1831) with significant intra- and inter-patient variability. For patients treated with 8, 10 and 12 g/m it was 587, 735 and 1114 μmol/l, respectively (P
Original language | English |
---|---|
Pages (from-to) | 411-415 |
Number of pages | 5 |
Journal | Anti-Cancer Drugs |
Volume | 17 |
Issue number | 4 |
DOIs | |
Publication status | Published - Apr 2006 |
Keywords
- Chemotherapy
- Histologic response
- Methotrexate
- Osteosarcoma
ASJC Scopus subject areas
- Pharmacology
- Cancer Research
- Oncology